IB 

Union Calendar No. 434 

113TH CONGRESS 

2D SESSION H. R. 4771 

[Report No. 113–587, Parts I and II] 

To amend the Controlled Substances Act to more effectively regulate anabolic 

steroids. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 29, 2014 

Mr. PITTS (for himself and Mr. PALLONE) introduced the following bill; which 

was referred to the Committee on Energy and Commerce, and in addition 

to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions 

as fall within the jurisdiction of the committee concerned 

SEPTEMBER 15, 2014 

Additional sponsors: Mr. CHAFFETZ, Mr. BEN RAY LUJA ́N of New Mexico, 

Ms. SHEA-PORTER, Mr. AMODEI, and Ms. DUCKWORTH

SEPTEMBER 15, 2014 

Reported from the Committee on Energy and Commerce with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

SEPTEMBER 15, 2014 

Reported from the Committee on the Judiciary with an amendment; committed to the Committee of the Whole House on the State of the Union 

and ordered to be printed 

[Strike out all after the enacting clause and insert the part printed in boldface roman] 

[For text of introduced bill, see copy of bill as introduced on May 29, 2014] 


tkelley on DSK3SPTVN1PROD with BILLS
2 

•HR 4771 RH

A BILL 

To amend the Controlled Substances Act to more effectively 

regulate anabolic steroids. 


tkelley on DSK3SPTVN1PROD with BILLS
3 

•HR 4771 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Designer Anabolic Ster5 oid Control Act of 2014’’. 

6 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

7 ACT. 

8 (a) DEFINITIONS.—Section 102(41) of the Controlled 

9 Substances Act (21 U.S.C. 802(41)) is amended— 

10 (1) in subparagraph (A)— 

11 (A) in clause (xlix), by striking ‘‘and’’ at 

12 the end; 

13 (B) by redesignating clause (xlx) as clause 

14 (lxxv); and 

15 (C) by inserting after clause (xlix) the fol16 lowing: 

17 ‘‘(l) 5α-Androstan-3,6,17-trione; 

18 ‘‘(li) 6-bromo-androstan-3,17-dione; 

19 ‘‘(lii) 6-bromo-androsta-1,4-diene-3,17-dione; 

20 ‘‘(liii) 4-chloro-17α-methyl-androsta-1,4-diene21 3,17β-diol; 

22 ‘‘(liv) 4-chloro-17α-methyl-androst-4-ene-3β,17β23 diol; 

24 ‘‘(lv) 4-chloro-17α-methyl-17β-hydroxy-androst25 4-en-3-one; 


tkelley on DSK3SPTVN1PROD with BILLS
4 

•HR 4771 RH

1 ‘‘(lvi) 4-chloro-17α-methyl-17β-hydroxy-androst2 4-ene-3,11-dione; 

3 ‘‘(lvii) 4-chloro-17α-methyl-androsta-1,4-diene4 3,17β-diol; 

5 ‘‘(lviii) 2α,17α-dimethyl-17β-hydroxy-5α6 androstan-3-one; 

7 ‘‘(lix) 2α,17α-dimethyl-17β-hydroxy-5β8 androstan-3-one; 

9 ‘‘(lx) 2α,3α-epithio-17α-methyl-5α-androstan10 17β-ol; 

11 ‘‘(lxi) [3,2-c]-furazan-5α-androstan-17β-ol; 

12 ‘‘(lxii) 3β-hydroxy-estra-4,9,11-trien-17-one; 

13 ‘‘(lxiii) 17α-methyl-androst-2-ene-3,17β-diol; 

14 ‘‘(lxiv) 17α-methyl-androsta-1,4-diene-3,17β-diol; 

15 ‘‘(lxv) Estra-4,9,11-triene-3,17-dione; 

16 ‘‘(lxvi) 18a-Homo-3-hydroxy-estra-2,5(10)-dien17 17-one; 

18 ‘‘(lxvii) 6α-Methyl-androst-4-ene-3,17-dione; 

19 ‘‘(lxviii) 17α-Methyl-androstan-3-hydroxyimine20 17β-ol; 

21 ‘‘(lxix) 17α-Methyl-5α-androstan-17β-ol; 

22 ‘‘(lxx) 17β-Hydroxy-androstano[2,3-d]isoxazole; 

23 ‘‘(lxxi) 17β-Hydroxy-androstano[3,2-c]isoxazole; 

24 ‘‘(lxxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2- 

25 c]pyrazole-5α-androstan-17β-ol; 


tkelley on DSK3SPTVN1PROD with BILLS
5 

•HR 4771 RH

1 ‘‘(lxxiii) [3,2-c]pyrazole-androst-4-en-17β-ol; 

2 ‘‘(lxxiv) [3,2-c]pyrazole-5α-androstan-17β-ol; 

3 and’’; and 

4 (2) by adding at the end the following: 

5 ‘‘(C)(i) Subject to clause (ii), a drug or hor6 monal substance (other than estrogens, progestins, 

7 corticosteroids, and dehydroepiandrosterone) that is 

8 not listed in subparagraph (A) and is derived from, 

9 or has a chemical structure substantially similar to, 

10 1 or more anabolic steroids listed in subparagraph 

11 (A) shall be considered to be an anabolic steroid for 

12 purposes of this Act if— 

13 ‘‘(I) the drug or substance has been created 

14 or manufactured with the intent of producing a 

15 drug or other substance that either— 

16 ‘‘(aa) promotes muscle growth; or 

17 ‘‘(bb) otherwise causes a pharma18 cological effect similar to that of testos19 terone; or 

20 ‘‘(II) the drug or substance has been, or is 

21 intended to be, marketed or otherwise promoted 

22 in any manner suggesting that consuming it will 

23 promote muscle growth or any other pharma24 cological effect similar to that of testosterone. 


tkelley on DSK3SPTVN1PROD with BILLS
6 

•HR 4771 RH

1 ‘‘(ii) A substance shall not be considered to be a 

2 drug or hormonal substance for purposes of this sub3 paragraph if it— 

4 ‘‘(I) is— 

5 ‘‘(aa) an herb or other botanical; 

6 ‘‘(bb) a concentrate, metabolite, or ex7 tract of, or a constituent isolated directly 

8 from, an herb or other botanical; or 

9 ‘‘(cc) a combination of 2 or more sub10 stances described in item (aa) or (bb); 

11 ‘‘(II) is a dietary ingredient for purposes of 

12 the Federal Food, Drug, and Cosmetic Act (21 

13 U.S.C. 301 et seq.); and 

14 ‘‘(III) is not anabolic or androgenic. 

15 ‘‘(iii) In accordance with section 515(a), any 

16 person claiming the benefit of an exemption or excep17 tion under clause (ii) shall bear the burden of going 

18 forward with the evidence with respect to such exemp19 tion or exception.’’. 

20 (b) CLASSIFICATION AUTHORITY.—Section 201 of the 

21 Controlled Substances Act (21 U.S.C. 811) is amended by 

22 adding at the end the following: 

23 ‘‘(i) TEMPORARY AND PERMANENT SCHEDULING OF

24 RECENTLY EMERGED ANABOLIC STEROIDS.— 


tkelley on DSK3SPTVN1PROD with BILLS
7 

•HR 4771 RH

1 ‘‘(1) The Attorney General may issue a tem2 porary order adding a drug or other substance to the 

3 definition of anabolic steroids if the Attorney General 

4 finds that— 

5 ‘‘(A) the drug or other substance satisfies 

6 the criteria for being considered an anabolic ster7 oid under section 102(41) but is not listed in 

8 that section or by regulation of the Attorney 

9 General as being an anabolic steroid; and 

10 ‘‘(B) adding such drug or other substance to 

11 the definition of anabolic steroids will assist in 

12 preventing abuse or misuse of the drug or other 

13 substance. 

14 ‘‘(2) An order issued under paragraph (1) shall 

15 not take effect until 30 days after the date of the pub16 lication by the Attorney General of a notice in the 

17 Federal Register of the intention to issue such order 

18 and the grounds upon which such order is to be 

19 issued. The order shall expire not later than 24 

20 months after the date it becomes effective, except that 

21 the Attorney General may, during the pendency of 

22 proceedings under paragraph (6), extend the tem23 porary scheduling order for up to 6 months. 

24 ‘‘(3) The Attorney General shall transmit notice 

25 of an order proposed to be issued under paragraph (1) 


tkelley on DSK3SPTVN1PROD with BILLS
8 

•HR 4771 RH

1 to the Secretary of Health and Human Services. In 

2 issuing an order under paragraph (1), the Attorney 

3 General shall take into consideration any comments 

4 submitted by the Secretary in response to a notice 

5 transmitted pursuant to this paragraph. 

6 ‘‘(4) A temporary scheduling order issued under 

7 paragraph (1) shall be vacated upon the issuance of 

8 a permanent scheduling order under paragraph (6). 

9 ‘‘(5) An order issued under paragraph (1) is not 

10 subject to judicial review. 

11 ‘‘(6) The Attorney General may, by rule, issue a 

12 permanent order adding a drug or other substance to 

13 the definition of anabolic steroids if such drug or 

14 other substance satisfies the criteria for being consid15 ered an anabolic steroid under section 102(41). Such 

16 rulemaking may be commenced simultaneously with 

17 the issuance of the temporary order issued under 

18 paragraph (1).’’. 

19 (c) LABELING REQUIREMENTS.— 

20 (1) IN GENERAL.—The Controlled Substances Act 

21 is amended by inserting after section 305 (21 U.S.C. 

22 825) the following: 

23 ‘‘SEC. 305A. OFFENSES INVOLVING FALSE LABELING OF AN24 ABOLIC STEROIDS. 

25 ‘‘(a) UNLAWFUL ACTS.— 


tkelley on DSK3SPTVN1PROD with BILLS
9 

•HR 4771 RH

1 ‘‘(1) It shall be unlawful— 

2 ‘‘(A) to import into the United States or to 

3 export from the United States; 

4 ‘‘(B) to manufacture, distribute, dispense, 

5 sell, or offer to sell; or 

6 ‘‘(C) to possess with intent to manufacture, 

7 distribute, dispense, sell, or offer to sell; 

8 any anabolic steroid, or any product containing an 

9 anabolic steroid, that does not bear a label clearly 

10 identifying any anabolic steroid contained in such 

11 steroid or product by the nomenclature used by the 

12 International Union of Pure and Applied Chemistry 

13 (IUPAC). 

14 ‘‘(2)(A) A product described in subparagraph 

15 (B) is exempt from the International Union of Pure 

16 and Applied Chemistry nomenclature requirement of 

17 this subsection if such product is labeled in the man18 ner required under the Federal Food, Drug, and Cos19 metic Act. 

20 ‘‘(B) A product is described in this subpara21 graph if the product— 

22 ‘‘(i) is the subject of an approved applica23 tion as described in section 505(b) or (j) of the 

24 Federal Food, Drug, and Cosmetic Act; or 


tkelley on DSK3SPTVN1PROD with BILLS
10 

•HR 4771 RH

1 ‘‘(ii) is exempt from the provisions of sec2 tion 505 of such Act relating to new drugs be3 cause— 

4 ‘‘(I) it is intended solely for investiga5 tional use as described in section 505(i) of 

6 such Act; and 

7 ‘‘(II) such product is being used exclu8 sively for purposes of a clinical trial that is 

9 the subject of an effective investigational 

10 new drug application. 

11 ‘‘(b) CRIMINAL PENALTIES.—Any person who violates 

12 subsection (a) knowing, intending, or having reasonable 

13 cause to believe, that the substance or product is an anabolic 

14 steroid, or contains an anabolic steroid, shall be sentenced 

15 to a term of imprisonment of not more than 10 years, a 

16 fine not to exceed the greater of that authorized in accord17 ance with the provisions of title 18, United States Code, 

18 or $500,000 if the defendant is an individual or $2,500,000 

19 if the defendant is other than an individual, or both. 

20 ‘‘(c) CIVIL PENALTIES.— 

21 ‘‘(1) Any person who violates subsection (a) shall 

22 be subject to a civil penalty as follows: 

23 ‘‘(A) In the case of an importer, exporter, 

24 manufacturer, or distributor (other than as pro25 vided in subparagraph (B)), up to $500,000 per 


tkelley on DSK3SPTVN1PROD with BILLS
11 

•HR 4771 RH

1 violation. For purposes of this subparagraph, a 

2 violation is defined as each instance of importa3 tion, exportation, manufacturing, or distribu4 tion, and each anabolic steroid or product im5 ported, exported, manufactured, or distributed. 

6 ‘‘(B) In the case of a sale or offer to sell at 

7 retail, up to $25,000 per violation. For purposes 

8 of this subparagraph, each sale and each product 

9 offered for sale shall be considered a separate vio10 lation. Continued offers to sell by a person 10 or 

11 more days after written notice (including 

12 through electronic message) to the person by the 

13 Attorney General or the Secretary shall be con14 sidered additional violations. 

15 ‘‘(2) In this subsection, the term ‘product’ means 

16 a discrete article, either in bulk or in finished form 

17 prepared for sale. A number of articles, if similarly 

18 packaged and bearing identical labels, shall be consid19 ered as one product, but each package size, form, or 

20 differently labeled article shall be considered a sepa21 rate product. 

22 ‘‘(d) IDENTIFICATION AND PUBLICATION OF LIST OF

23 PRODUCTS CONTAINING ANABOLIC STEROIDS.— 

24 ‘‘(1) The Attorney General may, in his discre25 tion, collect data and analyze products to determine 


tkelley on DSK3SPTVN1PROD with BILLS
12 

•HR 4771 RH

1 whether they contain anabolic steroids and are prop2 erly labeled in accordance with this section. The At3 torney General may publish in the Federal Register 

4 or on the website of the Drug Enforcement Adminis5 tration a list of products that he has determined, 

6 based on substantial evidence, contain an anabolic 

7 steroid and are not labeled in accordance with this 

8 section. 

9 ‘‘(2) The absence of a product from the list re10 ferred to in paragraph (1) shall not constitute evi11 dence that the product does not contain an anabolic 

12 steroid.’’. 

13 (2) TABLE OF CONTENTS.—The table of contents 

14 for the Comprehensive Drug Abuse Prevention and 

15 Control Act of 1970 is amended by inserting after the 

16 item relating to section 305 the following: 

‘‘Sec. 305A. Offenses involving false labeling of anabolic steroids.’’. 

17 SECTION 1. SHORT TITLE. 

18 This Act may be cited as the ‘‘Designer An19 abolic Steroid Control Act of 2014’’. 

20 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

21 ACT. 

22 (a) DEFINITIONS.—Section 102(41) of the 

23 Controlled Substances Act (21 U.S.C. 802(41)) 

24 is amended— 

25 (1) in subparagraph (A)— 


tkelley on DSK3SPTVN1PROD with BILLS
13 

•HR 4771 RH

1 (A) in clause (xlix), by striking 

2 ‘‘and’’ at the end; 

3 (B) by redesignating clause (xlx) 

4 as clause (lxxv); and 

5 (C) by inserting after clause (xlix) 

6 the following: 

7 ‘‘(l) 5α-Androstan-3,6,17-trione; 

8 ‘‘(li) 6-bromo-androstan-3,17-dione; 

9 ‘‘(lii) 6-bromo-androsta-1,4-diene-3,17- 

10 dione; 

11 ‘‘(liii) 4-chloro-17α-methyl-androsta12 1,4-diene-3,17β-diol; 

13 ‘‘(liv) 4-chloro-17α-methyl-androst-4- 

14 ene-3β,17β-diol; 

15 ‘‘(lv) 4-chloro-17α-methyl-17β-hydroxy16 androst-4-en-3-one; 

17 ‘‘(lvi) 4-chloro-17α-methyl-17β-hy18 droxy-androst-4-ene-3,11-dione; 

19 ‘‘(lvii) 4-chloro-17α-methyl-androsta20 1,4-diene-3,17β-diol; 

21 ‘‘(lviii) 2α,17α-dimethyl-17β-hydroxy22 5α-androstan-3-one; 

23 ‘‘(lix) 2α,17α-dimethyl-17β-hydroxy-5β24 androstan-3-one; 


tkelley on DSK3SPTVN1PROD with BILLS
14 

•HR 4771 RH

1 ‘‘(lx) 2α,3α-epithio-17α-methyl-5α2 androstan-17β-ol; 

3 ‘‘(lxi) [3,2-c]-furazan-5α-androstan-17β4 ol; 

5 ‘‘(lxii) 3β-hydroxy-estra-4,9,11-trien-17- 

6 one; 

7 ‘‘(lxiii) 17α-methyl-androst-2-ene8 3,17β-diol; 

9 ‘‘(lxiv) 17α-methyl-androsta-1,4-diene10 3,17β-diol; 

11 ‘‘(lxv) Estra-4,9,11-triene-3,17-dione; 

12 ‘‘(lxvi) 18a-Homo-3-hydroxy-estra13 2,5(10)-dien-17-one; 

14 ‘‘(lxvii) 6α-Methyl-androst-4-ene-3,17- 

15 dione; 

16 ‘‘(lxviii) 17α-Methyl-androstan-3- 

17 hydroxyimine-17β-ol; 

18 ‘‘(lxix) 17α-Methyl-5α-androstan-17β19 ol; 

20 ‘‘(lxx) 17β-Hydroxy-androstano[2,3- 

21 d]isoxazole; 

22 ‘‘(lxxi) 17β-Hydroxy-androstano[3,2- 

23 c]isoxazole; 

24 ‘‘(lxxii) 4-Hydroxy-androst-4-ene-3,17- 

25 dione[3,2-c]pyrazole-5α-androstan-17β-ol; 


tkelley on DSK3SPTVN1PROD with BILLS
15 

•HR 4771 RH

1 ‘‘(lxxiii) [3,2-c]pyrazole-androst-4-en2 17β-ol; 

3 ‘‘(lxxiv) [3,2-c]pyrazole-5α-androstan4 17β-ol; and’’; and 

5 (2) by adding at the end the fol6 lowing: 

7 ‘‘(C)(i) Subject to clause (ii), a drug or hor8 monal substance (other than estrogens, 

9 progestins, corticosteroids, and 

10 dehydroepiandrosterone) that is not listed in 

11 subparagraph (A) and is derived from, or has 

12 a chemical structure substantially similar to, 

13 1 or more anabolic steroids listed in subpara14 graph (A) shall be considered to be an ana15 bolic steroid for purposes of this Act if— 

16 ‘‘(I) the drug or substance has 

17 been created or manufactured with 

18 the intent of producing a drug or 

19 other substance that either— 

20 ‘‘(aa) promotes muscle growth; 

21 or 

22 ‘‘(bb) otherwise causes a phar23 macological effect similar to that 

24 of testosterone; or 


tkelley on DSK3SPTVN1PROD with BILLS
16 

•HR 4771 RH

1 ‘‘(II) the drug or substance has 

2 been, or is intended to be, marketed 

3 or otherwise promoted in any manner 

4 suggesting that consuming it will pro5 mote muscle growth or any other 

6 pharmacological effect similar to that 

7 of testosterone. 

8 ‘‘(ii) A substance shall not be consid9 ered to be a drug or hormonal substance 

10 for purposes of this subparagraph if it— 

11 ‘‘(I) is— 

12 ‘‘(aa) an herb or other botan13 ical; 

14 ‘‘(bb) a concentrate, metabo15 lite, or extract of, or a constituent 

16 isolated directly from, an herb or 

17 other botanical; or 

18 ‘‘(cc) a combination of 2 or 

19 more substances described in 

20 item (aa) or (bb); 

21 ‘‘(II) is a dietary ingredient for 

22 purposes of the Federal Food, Drug, 

23 and Cosmetic Act (21 U.S.C. 301 et 

24 seq.); and 


tkelley on DSK3SPTVN1PROD with BILLS
17 

•HR 4771 RH

1 ‘‘(III) is not anabolic or 

2 androgenic. 

3 ‘‘(iii) In accordance with section 

4 515(a), any person claiming the benefit of 

5 an exemption or exception under clause 

6 (ii) shall bear the burden of going for7 ward with the evidence with respect to 

8 such exemption or exception.’’. 

9 (b) CLASSIFICATION AUTHORITY.—Section 

10 201 of the Controlled Substances Act (21 

11 U.S.C. 811) is amended by adding at the end 

12 the following: 

13 ‘‘(i) TEMPORARY AND PERMANENT SCHED14 ULING OF RECENTLY EMERGED ANABOLIC

15 STEROIDS.— 

16 ‘‘(1) The Attorney General may issue a 

17 temporary order adding a drug or other 

18 substance to the definition of anabolic 

19 steroids if the Attorney General finds 

20 that— 

21 ‘‘(A) the drug or other substance 

22 satisfies the criteria for being consid23 ered an anabolic steroid under sec24 tion 102(41) but is not listed in that 

25 section or by regulation of the AttorVerDate Sep 11 2014 23:04 Sep 15, 2014 Jkt 039200 PO 00000 Frm 00017 Fmt 6652 Sfmt 6202 E:\BILLS\H4771.RH H4771

tkelley on DSK3SPTVN1PROD with BILLS
18 

•HR 4771 RH

1 ney General as being an anabolic 

2 steroid; and 

3 ‘‘(B) adding such drug or other 

4 substance to the definition of ana5 bolic steroids will assist in preventing 

6 abuse or misuse of the drug or other 

7 substance. 

8 ‘‘(2) An order issued under paragraph 

9 (1) shall not take effect until 30 days after 

10 the date of the publication by the Attor11 ney General of a notice in the Federal 

12 Register of the intention to issue such 

13 order and the grounds upon which such 

14 order is to be issued. The order shall ex15 pire not later than 24 months after the 

16 date it becomes effective, except that the 

17 Attorney General may, during the pend18 ency of proceedings under paragraph (6), 

19 extend the temporary scheduling order 

20 for up to 6 months. 

21 ‘‘(3) The Attorney General shall trans22 mit notice of an order proposed to be 

23 issued under paragraph (1) to the Sec24 retary of Health and Human Services. In 

25 issuing an order under paragraph (1), the 


tkelley on DSK3SPTVN1PROD with BILLS
19 

•HR 4771 RH

1 Attorney General shall take into consid2 eration any comments submitted by the 

3 Secretary in response to a notice trans4 mitted pursuant to this paragraph. 

5 ‘‘(4) A temporary scheduling order 

6 issued under paragraph (1) shall be va7 cated upon the issuance of a permanent 

8 scheduling order under paragraph (6). 

9 ‘‘(5) An order issued under paragraph 

10 (1) is not subject to judicial review. 

11 ‘‘(6) The Attorney General may, by 

12 rule, issue a permanent order adding a 

13 drug or other substance to the definition 

14 of anabolic steroids if such drug or other 

15 substance satisfies the criteria for being 

16 considered an anabolic steroid under sec17 tion 102(41). Such rulemaking may be 

18 commenced simultaneously with the 

19 issuance of the temporary order issued 

20 under paragraph (1).’’. 

21 SEC. 3. LABELING REQUIREMENTS. 

22 (a) IN GENERAL.—Section 305 of the Con23 trolled Substances Act (21 U.S.C. 825) is 

24 amended by adding at the end the following: 


tkelley on DSK3SPTVN1PROD with BILLS
20 

•HR 4771 RH

1 ‘‘(e) FALSE LABELING OF ANABOLIC

2 STEROIDS.— 

3 ‘‘(1) It shall be unlawful to import, ex4 port, manufacture, distribute, dispense, 

5 or possess with intent to manufacture, 

6 distribute, or dispense, an anabolic ster7 oid or product containing an anabolic 

8 steroid, unless the steroid or product 

9 bears a label clearly identifying an ana10 bolic steroid or product containing an an11 abolic steroid by the nomenclature used 

12 by the International Union of Pure and 

13 Applied Chemistry (IUPAC). 

14 ‘‘(2)(A) A product described in sub15 paragraph (B) is exempt from the Inter16 national Union of Pure and Applied 

17 Chemistry nomenclature requirement of 

18 this subsection if such product is labeled 

19 in the manner required under the Fed20 eral Food, Drug, and Cosmetic Act. 

21 ‘‘(B) A product is described in this 

22 subparagraph if the product— 

23 ‘‘(i) is the subject of an approved 

24 application as described in section 


tkelley on DSK3SPTVN1PROD with BILLS
21 

•HR 4771 RH

1 505(b) or (j) of the Federal Food, 

2 Drug, and Cosmetic Act; or 

3 ‘‘(ii) is exempt from the provisions 

4 of section 505 of such Act relating to 

5 new drugs because— 

6 ‘‘(I) it is intended solely for in7 vestigational use as described in 

8 section 505(i) of such Act; and 

9 ‘‘(II) such product is being 

10 used exclusively for purposes of a 

11 clinical trial that is the subject of 

12 an effective investigational new 

13 drug application.’’. 

14 (b) CLARIFICATION TO IMPORT AND EXPORT

15 STATUTE.—Section 1010 of the Controlled Sub16 stances Import and Export Act (21 U.S.C. 960) 

17 is amended, in subsection (a)(1), by inserting 

18 ‘‘305,’’ before ‘‘1002’’. 

19 (c) CIVIL PENALTIES.—Section 402 of the 

20 Controlled Substances Act (21 U.S.C. 842) is 

21 amended— 

22 (1) in subsection (a)— 

23 (A) in paragraph (14), by striking 

24 ‘‘or’’ at the end; 


tkelley on DSK3SPTVN1PROD with BILLS
22 

•HR 4771 RH

1 (B) in paragraph (15), by striking 

2 the period at the end and inserting ‘‘; 

3 or’’; and 

4 (C) by inserting, after paragraph 

5 (15), the following: 

6 ‘‘(16) to violate subsection (e) of sec7 tion 305 of the Controlled Substances 

8 Act.’’; and 

9 (2) in subsection (c)(1)— 

10 (A) by inserting, in subparagraph 

11 (A), after ‘‘subparagraph (B)’’ the fol12 lowing: ‘‘, (C), or (D)’’; and 

13 (B) by inserting after subpara14 graph (B) the following: 

15 ‘‘(C) In the case of a violation of para16 graph (16) of subsection (a) of this section by 

17 an importer, exporter, manufacturer, or dis18 tributor (other than as provided in subpara19 graph (D)), up to $500,000 per violation. For 

20 purposes of this subparagraph, a violation is 

21 defined as each instance of importation, ex22 portation, manufacturing, distribution, or 

23 possession with intent to manufacture or dis24 tribute, in violation of paragraph (16) of sub25 section (a). 


tkelley on DSK3SPTVN1PROD with BILLS
23 

•HR 4771 RH

1 ‘‘(D) In the case of a distribution, dis2 pensing, or possession with intent to dis3 tribute or dispense in violation of paragraph 

4 (16) of subsection (a) of this section at the re5 tail level, up to $1000 per violation. For pur6 poses of this paragraph, the term ‘at the retail 

7 level’ refers to products sold, or held for sale, 

8 directly to the consumer for personal use. 

9 Each package, container or other separate 

10 unit containing an anabolic steroid that is dis11 tributed, dispensed, or possessed with intent 

12 to distribute or dispense at the retail level in 

13 violation of paragraph (16) of subsection (a) 

14 shall be considered a separate violation.’’. 

15 SEC. 4. IDENTIFICATION AND PUBLICATION OF LIST OF 

16 PRODUCTS CONTAINING ANABOLIC 

17 STEROIDS. 

18 (a) The Attorney General may, in his dis19 cretion, collect data and analyze products to 

20 determine whether they contain anabolic 

21 steroids and are properly labeled in accord22 ance with this section. The Attorney General 

23 may publish in the Federal Register or on the 

24 website of the Drug Enforcement Administra25 tion a list of products that he has determined, 


tkelley on DSK3SPTVN1PROD with BILLS
24 

•HR 4771 RH

1 based on substantial evidence, contain an an2 abolic steroid and are not labeled in accord3 ance with this section. 

4 (b) The absence of a product from the list 

5 referred to in subsection (a) shall not con6 stitute evidence that the product does not 

7 contain an anabolic steroid. 


tkelley on DSK3SPTVN1PROD with BILLS

tkelley on DSK3SPTVN1PROD with BILLS
Union Calendar No. 434 

113TH CONGRESS 

2D SESSION H. R. 4771 

[Report No. 113–587, Parts I and II] 

A BILL 

To amend the Controlled Substances Act to more 

effectively regulate anabolic steroids. 

SEPTEMBER 15, 2014 

Reported from the Committee on Energy and Commerce 

with an amendment 

SEPTEMBER 15, 2014 

Reported from the Committee on the Judiciary with an 

printed House on the State of the Union and ordered to be amendment; committed to the Committee of the Whole 


tkelley on DSK3SPTVN1PROD with BILLS